Literature DB >> 26350885

Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.

R N Werner1, A Jacobs1, S Rosumeck1, R Erdmann1, B Sporbeck1, A Nast1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26350885     DOI: 10.1111/jdv.13179

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  5 in total

Review 1.  [Current guidelines in dermatology : A selection of clinically relevant recommendations].

Authors:  A Nast; S Rosumeck; R Erdmann; C Dressler; R N Werner
Journal:  Hautarzt       Date:  2016-05       Impact factor: 0.751

2.  Pulsed Dye Laser-mediated Photodynamic Therapy is Less Effective than Conventional Photodynamic Therapy for Actinic Field Cancerization: A Randomized Half-side Comparative Study.

Authors:  Vivian Lindholm; Sari Pitkänen; Marika Schröder; Sonja Hahtola; Helka Sahi; Heini Halme; Kirsi Isoherranen
Journal:  Acta Derm Venereol       Date:  2021-02-19       Impact factor: 3.875

3.  Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp.

Authors:  Nevena Skroza; Ilaria Proietti; Nicoletta Bernardini; Veronica Balduzzi; Alessandra Mambrin; Anna Marchesiello; Ersilia Tolino; Sara Zuber; Giuseppe La Torre; Concetta Potenza
Journal:  World J Clin Oncol       Date:  2017-10-10

Review 4.  Topical Pharmacotherapy for Actinic Keratoses in Older Adults.

Authors:  Piergiacomo Calzavara-Pinton; Irene Calzavara-Pinton; Chiara Rovati; Mariateresa Rossi
Journal:  Drugs Aging       Date:  2022-02-14       Impact factor: 3.923

5.  Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel.

Authors:  Sonia Segura; Alejandra Gadea; Lara Nonell; Evelyn Andrades; Silvia Sánchez; Ramon Pujol; Inmaculada Hernández-Muñoz; Agustí Toll
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.